InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more
InnoTherapy Inc - Asset Resilience Ratio
InnoTherapy Inc (246960) has an Asset Resilience Ratio of 4.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how InnoTherapy Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down InnoTherapy Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.61 Billion | 4.79% |
| Total Liquid Assets | ₩3.61 Billion | 4.79% |
Asset Resilience Insights
- Limited Liquidity: InnoTherapy Inc maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
InnoTherapy Inc Industry Peers by Asset Resilience Ratio
Compare InnoTherapy Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for InnoTherapy Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for InnoTherapy Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.63% | ₩1.11 Billion | ₩24.06 Billion | -24.49pp |
| 2023-12-31 | 29.12% | ₩8.78 Billion | ₩30.16 Billion | +16.48pp |
| 2022-12-31 | 12.64% | ₩3.89 Billion | ₩30.81 Billion | -20.05pp |
| 2021-12-31 | 32.68% | ₩10.42 Billion | ₩31.88 Billion | +5.95pp |
| 2020-12-31 | 26.73% | ₩4.64 Billion | ₩17.35 Billion | -35.67pp |
| 2019-12-31 | 62.40% | ₩10.75 Billion | ₩17.23 Billion | +32.50pp |
| 2018-12-31 | 29.90% | ₩3.34 Billion | ₩11.18 Billion | +24.62pp |
| 2017-12-31 | 5.28% | ₩222.05 Million | ₩4.20 Billion | -24.25pp |
| 2016-12-31 | 29.53% | ₩2.08 Billion | ₩7.03 Billion | +3.29pp |
| 2015-12-31 | 26.24% | ₩2.13 Billion | ₩8.11 Billion | -- |